- Home
- CELC vs EYE Comparison
CELC vs EYE Comparison
Compare CELC & EYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- EYE
- Stock Information
- Founded
- CELC 2011
- EYE 1990
- Country
- CELC United States
- EYE United States
- Employees
- CELC N/A
- EYE N/A
- Industry
- CELC Medical Specialities
- EYE Ophthalmic Goods
- Sector
- CELC Health Care
- EYE Health Care
- Exchange
- CELC Nasdaq
- EYE Nasdaq
- Market Cap
- CELC 2.3B
- EYE 1.9B
- IPO Year
- CELC 2017
- EYE 2017
- Fundamental
- Price
- CELC $50.51
- EYE $28.87
- Analyst Decision
- CELC Strong Buy
- EYE Buy
- Analyst Count
- CELC 6
- EYE 9
- Target Price
- CELC $63.00
- EYE $21.78
- AVG Volume (30 Days)
- CELC 1.0M
- EYE 2.1M
- Earning Date
- CELC 11-13-2025
- EYE 11-05-2025
- Dividend Yield
- CELC N/A
- EYE N/A
- EPS Growth
- CELC N/A
- EYE N/A
- EPS
- CELC N/A
- EYE N/A
- Revenue
- CELC N/A
- EYE $1,885,540,000.00
- Revenue This Year
- CELC N/A
- EYE $8.59
- Revenue Next Year
- CELC N/A
- EYE $3.43
- P/E Ratio
- CELC N/A
- EYE N/A
- Revenue Growth
- CELC N/A
- EYE 5.08
- 52 Week Low
- CELC $7.58
- EYE $9.56
- 52 Week High
- CELC $63.06
- EYE $29.60
- Technical
- Relative Strength Index (RSI)
- CELC 49.45
- EYE 67.70
- Support Level
- CELC $44.42
- EYE $28.42
- Resistance Level
- CELC $52.76
- EYE $29.60
- Average True Range (ATR)
- CELC 3.10
- EYE 1.16
- MACD
- CELC -1.11
- EYE 0.29
- Stochastic Oscillator
- CELC 51.39
- EYE 88.28
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About EYE National Vision Holdings Inc.
National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.